Lifastuzumab vedotin

Add links
Source: Wikipedia, the free encyclopedia.
Lifastuzumab vedotin
Humanized (from mouse)
Targetphosphate-sodium cotransporter
Clinical data
Other namesDNIB0600A
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6504H10028N1744O2018S46
Molar mass146416.72 g·mol−1

Lifastuzumab vedotin (

antibody-drug conjugate designed for the treatment of cancer.[2]

This drug was developed by

Roche
.

References

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lifastuzumab Vedotin, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lifastuzumab_vedotin&oldid=1184785995"